Veradermics

14 days ago · seekingalpha.com

Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript

14 days ago · marketbeat.com

Veradermics NYSE: MANE reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss.

14 days ago · businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304') evaluating VDPHL01, a proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern h.

15 days ago · businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304') evaluating VDPHL01, a proprietary, extended-re.

15 days ago · gurufocus.com

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern

2 months ago · businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi's 2026 Biopharma Back to School Conference Presentation: Wednesd.

3 months ago · businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the p.

4 months ago · seekingalpha.com

MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.

4 months ago · businesswire.com

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, 2026, and will be shared in an oral presentation on July 17, 2026, during th.

4 months ago · benzinga.com

Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.